Zacks Analyst Blog Highlights Visa, Walt Disney, Abbott Laboratories, Nike and United Parcel Service
For immediate release
Chicago, IL – April 29, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Visa Inc. V, The Walt Disney Co. DIS, Abbott Laboratories ABT, Nike, Inc. NKE, and United Parcel Service, Inc. UPS.
Here are highlights from Thursday’s analyst blog:
Key analyst reports for Visa, Walt Disney and Abbott
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Visa Inc., The Walt Disney Co. and Abbott Laboratories. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all today’s research reports here >>>
Shares of Visa have outperformed the Zacks financial transaction services sector year-to-date (+1.8% vs -3.5%). The company’s earnings in the second quarter of fiscal 2022 beat estimates on high payout volume. Numerous buyouts and alliances paved the way for long-term growth and consistently boosted its revenue.
Its investments in technology strengthen its position in the payments market. A transition of payments to digital mode is a godsend. Deployments of coronavirus vaccines and the gradual upturn in consumer confidence will continue to drive spending, in turn increasing business volumes.
With its strong cash position, the company remains committed to increasing its shareholder value. However, high operating costs weigh on margins. Increasing customer incentives will affect turnover. Its declining liquidity volume from Asia-Pacific is disturbing. Its volumes will probably suffer from the Russian-Ukrainian situation.
(You can read the full Visa research report here >>>)
waltz disney shares are down -38.7% over the past year against media conglomerate Zacks’ industry decline of -40.8%. The company’s profitability is expected to be negatively affected by rising programming and production costs. Disney expects continued investment in its owned and produced content for direct-to-consumer services to hurt operating income.
The closure of its Shanghai theme park due to COVID-19 does not bode well for near-term park, experience and product revenue. Disney’s leveraged balance sheet also remains a concern.
However, thanks to a strong content portfolio and a cheaper bundle. Availability in the Nordics, Latin America, and other Asian territories should help expand the user base. The relaunch of the Parks, Experiences and Products activities is also promising.
(You can read the full research report on Walt Disney here >>>)
Abbott shares are down -1.2% over the past year against the industry’s -23.9% decline Zacks Medical – Products. The company’s pediatric nutrition sales were negatively impacted by a voluntary recall of certain powdered formulas manufactured at one of Abbott’s US factories. With the exception of Nutrition (where the company recorded a 4.4% year-over-year decline on an organic basis), the company recorded organic sales growth in all of its major operating segments . Global sales related to COVID-19 tests were dominated by sales of rapid test products.
Within Diabetes Care, the company was honored for the developments of its flagship sensor-based continuous glucose monitoring system, FreeStyle Libre. In adult nutrition, the company benefited from the solid performance of the Ensure and Glucerna brands.
(You can read the full research report on Abbott here >>>)
Other noteworthy reports we feature today include Nike, Inc. and United Parcel Service, Inc.
Why haven’t you watched Zacks best action?
Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.
See Free Stocks >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. To visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
7 best stocks for the next 30 days
Just Released: Experts distill 7 elite stocks from the current Zacks No. 1 Ranking 220 Strong Buys list. They consider these tickers “most likely for early price increases.”
Since 1988, the full list has beaten the market more than 2 times with an average gain of +25.4% per year. So be sure to give your immediate attention to these 7 handpicked ones.
Discover them now >>
Click to get this free report
Abbott Laboratories (ABT): Free Inventory Analysis Report
Visa Inc. (V): Free Stock Analysis Report
NIKE, Inc. (NKE): Free Stock Analysis Report
United Parcel Service, Inc. (UPS): Free Inventory Analysis Report
The Walt Disney Company (DIS): Free Inventory Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
